To stimulate an open dialogue with companies interested in the ARCHIVER project, all information given in answers to questions raised by potential suppliers will be documented and published in this FAQ.

This page will be regularly updated as new questions are answered.

Procurement / Legal:

What will be the time period during which contractors have to commercially exploit the results of the PCP before ownership of the results transfers to the Buyers Group ?

This time period has not been fixed yet. However, and as an indication, in HelixNebula Science Cloud, the last PCP project coordinated by CERN,  the contractors were given 2 years to commercially exploit their results.  The time period for ARCHIVER will be confirmed in the Framework Agreement final draft released with the Request for Tenders.

How will the actual price and virtual price be used to evaluate tenders ?

It is likely that only the actual price will be taken into consideration for the evaluation of the bids. The final evaluation criteria and formula will be indicated in the Request for Tenders.

If firms reply to the Request for Tender in a Consortium, do the firms need to be from the  same country?

No. Firms replying to the Request for Tender in a Consortium can be from the same country or from different countries. There is no restriction on where firms responding to the Request for Tender have to be located. However, it is a requirement of the PCP that the majority of the R&D activities, including the main researchers working on the contracts, be located in EU Member States or Horizon 2020 Associated Countries.

Any Results we develop would be significantly based on our Background IP. Considering that, how is it possible for you to use and possibly sublicence the Results?

The Buyers Group will require a sub-licensable licence to use the Results for the purposes of the Framework Agreement and for their own non-commercial use. This would include a sub-licensable right to use any Background IP or Sideground IP owned by the contractor that is necessary for the use of the Results for the afore-mentioned non-commercial purposes.
In addition, the Buyers Group may require a sub-licensable licence to exploit the Results.
This would include a sub-licensable right to exploit any Background IP or Sideground IP owned by the contractor that is necessary for the exploitation of the Results. However, any such licence would be granted under fair and reasonable conditions which may include financial compensation for the contractor. It is also intended that a one year “embargo” period would apply before the Buyers Group may require any such licence.
Please refer to the draft Framework Agreement section 7.3 for further details. In order to distinguish between Background IP and Results, the first deliverable you will have to provide under the PCP contracts is a declaration of your Background IP.


Deployment Scenarios:

Where is the data from the deployment scenarios ingested from? Is the ingest done after data calibration/validation? Are there more scenarios?

Typically, raw data has to be calibrated and validated before ANY scientific process can take place. The goal is not to pour bits as far as possible into a bucket. The goal is to ingest those bits together with all the necessary associated information into a long-term OAIS preservation archive.

What Quality of Service (QoS) guarantees does GÉANT have?

As GÉANT is not a commercial network operator,  it does not provide guarantees or SLAs but Service Level Targets. GÉANT Service Level Targets can be found here. Information about the QoS can be found in the Monthly Service reports. However the QoS is also dependent on the specific path or network segment. For more information on the process to connect to GÉANT can be found on section 2.2.1 of the Draft Functional Specification.

Is the replication of the data partial? Are there multiple different scenarios?

There are multiple different cases for data replication. For the majority of the deployment scenarios, the Buyers Group has several copies held within the same system but no external disaster recovery mechanism.

In which scenario(s) are we looking into full remote archive deployments?

All of the proposed deployment scenarios would benefit from full remote archive deployments.

What are the data access patterns requirements (how diverse and how complex for the deployments/use cases presented)?

The data access patterns vary drastically from one deployment scenario to another. There are cases where data are very rarely recalled, e.g.even less than once in a year, but there are also cases in which data might need to be accessed on a daily basis.

What is the distribution pattern for the Life Sciences deployment scenario?

The answer will be published shortly

In the deployment scenarios from DESY,  it is required that a user can manage / add new versions (state) of derived/added data to existing archives. Does this correspond to storing delta ?

The answer will be published shortly

Is Food and Drug Administration (FDA) regulation relevant for the Life Sciences Deployment Scenarios?

The answer will be published shortly

The CERN Open Data Portal deployment scenario is referring to the XRootD protocol. Can you provide more information?

The answer will be published shortly


Click here to add a question to the FAQ





"Digital preservation exists already for more than 20 years. For lots of problems there are already solutions". Barbara Sierman, chair of the Open Preservation Foundation Board and Digital Preservation consultant at the Koninklijke Bibliotheek (KB), works as an advisor on various topics related to the preservation and long-term accessibility of digital collections.

João Fernandes, CERN and Archiver coordinator, will explain Archiver innovation potential to service providers, research managers and procurement and purchasing experts gathered in Prague for the EOSC-Hub week